Company intelligence / Profile preview

EBI Anti Sepsis

Gosselies, Belgium

Ownership: Private
Development stage: Other

Overview

EBI (EBI S.A.) was a Belgian biotechnology company focused on the development of innovative therapies for inflammatory diseases, with a primary focus on sepsis. The company's lead program was a monoclonal antibody designed to neutralize Complement C5a, a key mediator in the inflammatory cascade that leads to septic shock. EBI was founded as a spin-off from the Université Libre de Bruxelles (ULB) and leveraged research from the Institute of Medical Immunology. The company was eventually acquired by the German biotech InflaRx, which integrated EBI's assets into its own anti-C5a pipeline.

Therapeutic areas: Infectious Diseases
Modalities: Monoclonal antibodyAntibody
Industry: Biotech

Partnerships

Université Libre de Bruxelles

Beyond the preview

Go deeper on EBI Anti Sepsis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EBI Anti Sepsis.

Explore the full profile